A multicenter randomized controlled trial on the efficacy of intradiscal methylene blue injection for chronic discogenic low back pain: the IMBI study

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in the context of chronic pain: fibromyalgia & crps in this randomized controlled trial publication.

The researchers replicated the design of the previously published study and performed a multicenter, double-blind, randomized, placebo-controlled trial to assess whether the extraordinary effects of MB on pain intensity could be confirmed.

Who Took Part

The study group was 84 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

As a double-blind Methylene blue (non-peptide stack partner) study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Methylene blue (non-peptide stack partner), giving a reference point.

More than one site took part, so the patients came from several places.

What Was Measured

Topics PubMed links to this paper include Enzyme Inhibitors, Intervertebral Disc, Intervertebral Disc Displacement, Low Back Pain, Methylene Blue, Pain Measurement and Quality of Life.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner) in 84 patients in people with chronic pain: fibromyalgia & crps.

The publication is from 2019 (Pain), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, Chronic pain: fibromyalgia & CRPS research.